MOTS-c: the mitochondria-derived peptide in the literature

Discovered in 2015, encoded by mitochondrial DNA, and studied primarily in animal models. Here’s what the research actually shows.

TL;DR

• MOTS-c is a 16-amino-acid peptide encoded by the 12S rRNA gene in mitochondrial DNA — making it one of a newly recognized class of mitochondria-derived peptides.
• Published animal research documents AMPK activation, metabolic regulation, and exercise-capacity effects; human clinical data is very limited.
• As of publication, MOTS-c is classified as Category 2 and is not available from 503A compounding pharmacies.

What it is

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a peptide discovered by Lee et al. in 2015 and reported in Cell Metabolism. What makes it unusual is its origin: unlike most peptides encoded by nuclear DNA, MOTS-c is encoded by the mitochondrial genome — specifically within a reading frame of the 12S ribosomal RNA gene. Mitochondria are the energy-producing organelles in cells, and the discovery of peptides encoded by their genome opened a new area of research sometimes called mitochondrial endocrinology. MOTS-c is produced in mitochondria and can translocate to the nucleus, where it appears to regulate gene expression in response to metabolic stress.

How it works

The primary mechanism identified in the Lee et al. discovery paper involves activation of AMPK — AMP-activated protein kinase, a cellular energy sensor that is activated when ATP levels fall. AMPK activation broadly shifts cellular metabolism toward fat oxidation, improves insulin sensitivity, and inhibits anabolic processes that consume ATP. In the original mouse studies, MOTS-c administration improved insulin sensitivity, reduced diet-induced obesity, and enhanced exercise capacity. Later research (Kim et al., 2018) demonstrated that MOTS-c levels in blood decline with age in both mice and humans, positioning it as a potential marker of mitochondrial function and a candidate for study in age-related metabolic decline.

Who asks about it

MOTS-c comes up in mitochondrial health and longevity discussions, particularly among people who have encountered the concept of “mitokines” — peptides released by mitochondria that signal to other tissues. It also appears in exercise performance and metabolic optimization conversations. Its novelty — it’s been known for barely a decade — makes it an area where understanding what we don’t yet know is as important as understanding what we do.

What the research says

The foundational Lee et al. (2015) paper in Cell Metabolism remains the most-cited reference. In mouse models, MOTS-c injections reduced diet-induced insulin resistance, with effects similar to exercise. The 2018 Kim et al. paper in Proceedings of the National Academy of Sciences documented declining MOTS-c levels with age in both mice and humans, adding epidemiological interest. Human clinical trials are essentially absent from the literature; the compound has not progressed to Phase I safety evaluation in a published US trial context.

What to know before considering it

MOTS-c’s regulatory status as Category 2 is the immediate barrier: it is not available from 503A compounding pharmacies in the United States as of publication. A February 2026 HHS announcement proposed returning certain Category 2 peptides to Category 1 pending formal Federal Register rulemaking, but that is not yet final. Beyond the regulatory issue, the jump from mouse metabolic models to human clinical use involves enormous uncertainty — dosing, route, frequency, and long-term effects are all unknown.

The Halftime POV

MOTS-c is at an early but genuinely interesting place in the longevity science arc. The discovery that mitochondria produce signaling peptides that regulate metabolism across tissues is a real scientific development — not hype. The honest position is that the human chapter of this story hasn’t been written yet. When it is, we’ll cover it.

Related reading:

• Age Related Decline Basics
• Category 1 Vs Category 2
• Rfk Peptide Reclassification

FAQ

Q: What is MOTS-c? A: MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA-c) is a peptide encoded by mitochondrial DNA, first identified in 2015. It is a naturally occurring mitochondria-derived peptide (MDP) that acts as a metabolic regulator, activating AMPK pathways. Its discovery was described in Cell Metabolism by Lee et al. (2015).

Q: What does published research show about MOTS-c? A: Animal studies have documented effects on metabolic function, exercise capacity, and glucose regulation following MOTS-c administration. Lee et al. (2015) showed MOTS-c injection in mice improved insulin sensitivity and reduced diet-induced obesity. Human clinical trial data is sparse as of 2026. It is Category 2 and not currently available from 503A pharmacies.

Q: Is MOTS-c available through a compounding pharmacy? A: No. As of April 2026, MOTS-c is classified as Category 2 under the FDA’s 503A framework and cannot be legally dispensed by a compounding pharmacy. A February 2026 HHS announcement proposed returning some Category 2 peptides to Category 1, but formal Federal Register notice had not been published at time of writing.

Disclaimer

As of April 2026, MOTS-c is classified by the FDA as Category 2, which means it is not currently available from 503A compounding pharmacies. A February 2026 HHS announcement proposed returning these peptides to Category 1 pending formal FDA Federal Register notice. This article is educational and is not medical advice. Halftime Health only prescribes through licensed clinicians in states where our partner physicians are credentialed.

Get updates

Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.

Sources

• Lee C et al. “The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.” — Cell Metab, 2015
• Kim KH et al. “Mitochondrial peptide MOTS-c is a regulator of plasma metabolites and is associated with aging-related diseases.” — Proc Natl Acad Sci USA, 2018

This article discusses compounds that are currently under FDA Category 2 review (see our FDA categorization explainer). These compounds are not currently part of Halftime Health’s published protocol catalog. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.